Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

September 4, 2025

Study Completion Date

September 4, 2025

Conditions
Cystic Fibrosis
Interventions
DRUG

ELX/TEZ/IVA

Fixed-dose combination granules for oral administration.

DRUG

IVA

Granules for oral administration

Trial Locations (19)

Unknown

Telethon Kids Institute, Nedlands

The Royal Children's Hospital, Parkville

Queensland Children's Hospital, South Brisbane

The Children's Hospital at Westmead, Westmead

The Hospital for Sick Children, Toronto

British Columbia Children's Hospital, Vancouver

Juliane Marie Center, Rigshospitalet, Copenhagen

Charite Paediatric Pulmonology Department, Berlin

Kinderklinik III, Abt. fur Pneumologie, Essen

Medizinische Hochschule Hannover, Hanover

Erasmus Medical Center / Sophia Children's Hospital, Rotterdam

Inselspital - Universitaetsspital Bern, Bern

Kinderspital Zuerich, Zurich

Children and Young Adults Research Unit, Cardiff

Leeds General Infirmary, Leeds

Alder Hey Children's NHS Foundation Trust, Liverpool

Great Ormond Street Hospital for Children, London

Royal Brompton Hospital, London

Southampton General Hospital, Southampton

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT05882357 - Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age | Biotech Hunter | Biotech Hunter